Citation Impact
Citing Papers
Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β
2016
Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER+ Breast Cancer
2016
eIF4E/4E-BP Ratio Predicts the Efficacy of mTOR Targeted Therapies
2012
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer
2016
Molecular Pathways: The eIF4F Translation Initiation Complex—New Opportunities for Cancer Treatment
2016
Measurement of PIP3 Levels Reveals an Unexpected Role for p110β in Early Adaptive Responses to p110α-Specific Inhibitors in Luminal Breast Cancer
2014
Hallmarks of Cancer: The Next Generation
2011 Standout
Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers
2013
Genetic variation at the 8q24.21 renal cancer susceptibility locus affects HIF binding to a MYC enhancer
2016 StandoutNobel
The PI3K/AKT Pathway as a Target for Cancer Treatment
2015
Update on the management of familial central nervous system tumor syndromes
2007
MYC on the Path to Cancer
2012 Standout
Brown and beige fat: development, function and therapeutic potential
2013 Standout
AKT/PKB Signaling: Navigating Downstream
2007 Standout
Pten Positively Regulates Brown Adipose Function, Energy Expenditure, and Longevity
2012
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Role of Oncogenes and Tumor-suppressor Genes in Carcinogenesis: A Review
2020 Standout
Shedding light on Merlin's wizardry
2007
Constitutive neuregulin‐1/ErbB signaling contributes to human vestibular schwannoma proliferation
2006
Synergy in activating class I PI3Ks
2015
Glioblastoma and Other Malignant Gliomas
2013 Standout
Rapamycin: One Drug, Many Effects
2014 Standout
Translational Control in Cancer Etiology
2012
Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets
2009 Standout
Should individual PI3 kinase isoforms be targeted in cancer?
2009
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
2016
Links between metabolism and cancer
2012
Opposing Roles for Akt1 and Akt2 in Rac/Pak Signaling and Cell Migration
2006
Merlin and the ERM proteins – regulators of receptor distribution and signaling at the cell cortex
2009
EGF–ERBB signalling: towards the systems level
2006 Standout
The TORrid affairs of viruses: effects of mammalian DNA viruses on the PI3K–Akt–mTOR signalling pathway
2008
Targeting the phosphoinositide 3-kinase pathway in cancer
2009 Standout
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
2013 StandoutNobel
Mammalian display screening of diverse cystine-dense peptides for difficult to drug targets
2017 StandoutNobel
mTOR Signaling in Growth, Metabolism, and Disease
2017 Standout
The Hippo Signaling Pathway in Development and Cancer
2010 Standout
Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain
2017 StandoutNobel
Widespread Translational Remodeling during Human Neuronal Differentiation
2017 StandoutNobel
Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy
2015
Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control
2007 Standout
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Serine 518 phosphorylation modulates merlin intramolecular association and binding to critical effectors important for NF2 growth suppression
2004
Programmed Cell Senescence during Mammalian Embryonic Development
2013 Standout
CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
2014
A metabolic labeling approach for glycoproteomic analysis reveals altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells
2016 StandoutNobel
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
2014
Cisplatin: The first metal based anticancer drug
2019 Standout
Targeting ferroptosis as a vulnerability in cancer
2022 Standout
Targeting the translation machinery in cancer
2015
Akt signalling in health and disease
2011 Standout
AKT/PKB Signaling: Navigating the Network
2017 Standout
Organizing the cell cortex: the role of ERM proteins
2010 Standout
The Warburg Effect: How Does it Benefit Cancer Cells?
2016 Standout
The Hallmarks of Aging
2013 Standout
Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells
2018 Standout
The PI3K Pathway in Human Disease
2017 Standout
Current treatment strategies for inhibiting mTOR in cancer
2014
ROS signalling in the biology of cancer
2017 Standout
Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer
2016
The phosphoinositide 3-kinase pathway and therapy resistance in cancer
2015
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
The integrated stress response
2016 Standout
Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms
2015
Arginine Deiminase Resistance in Melanoma Cells Is Associated with Metabolic Reprogramming, Glucose Dependence, and Glutamine Addiction
2013
Improving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assays
2016
Fundamentals of cancer metabolism
2016 Standout
mTOR coordinates protein synthesis, mitochondrial activity and proliferation
2015
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
2014 Standout
MYC, Metabolism, and Cancer
2015
Contact-dependent inhibition of EGFR signaling by Nf2/Merlin
2007
Tunable protein synthesis by transcript isoforms in human cells
2016 StandoutNobel
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α ( PIK3CA )
2012
Signalling to eIF4E in cancer
2015
Works of Tamara Utermark being referenced
PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis
2011
The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis
2012
A Clue to the Therapy of Neurofibromatosis Type 2
2004
A functional association between merlin and HEI10, a cell cycle regulator
2006
Impaired intercellular adhesion and immature adherens junctions in merlin‐deficient human primary schwannoma cells
2008
PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context
2014
The p110α Isoform of Phosphatidylinositol 3-Kinase Is Essential for Polyomavirus Middle T Antigen-Mediated Transformation
2007